Leukotrien receptor blockade in severe bronchoplumonary dysplasia as an idividual treatment attempt

Leukotrien receptor blockade in severe bronchoplumonary dysplasia as an idividual treatment attempt - BPD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004763

Enrollment

Registered

2013-03-13

Start date

2009-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

P27.1

Interventions

Group 1: Singulair (Montelukast) 1-2 mg/kg per day for at least 4 weeks p.o. in life threatening brochopulmonary dysplasie in preterm infants Group 2: no Montelukast therapy

Eligibility

Sex/Gender

All

Age

28 Days to 12 Weeks

Inclusion criteria

Inclusion criteria: Premature babies before 32 weeks of gestation, after the 28th day of life, with life-threatening bronchopulmonary dysplasia and a need for mechanical ventilation on day 28 as an individual treatment attempt.

Exclusion criteria

Exclusion criteria: Contraindications for the study drug

Design outcomes

Primary

Measure	Time frame
survival at discharge from the hospital by questionnaire	—

Secondary

Measure	Time frame
pulmonary function at discharge from the hospital measured by a predefined score	—

Countries

Germany

Contacts

Public ContactThomas Rupprecht

Klinik für Kinder und Jugendliche

thomas.rupprecht@klinikum-bayreuth.de0921-4006202

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026